AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05063331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)
Description: Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
Study NCT05063331 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
Description: The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
Study NCT05172999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel-releasing intrauterine system
Description: Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
Study NCT05172999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: levonorgestrel-releasing intrauterine system
Description: Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
Study NCT05172999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Loxenatide
Description: Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
Study NCT05501262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.
Study NCT05501262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Ultrasound and fluoroscopic guided nerve block.
Study NCT05569811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg
Study NCT05569811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
Study NCT05569811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
Study NCT05753033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR750 tablet
Description: Ascending single and multiple doses of SR750 orally
Study NCT05753033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of placebo orally
Study NCT04764162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: 1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)
Study NCT04764162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules
Study NCT06534944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: NR 1g daily for 4 weeks
Study NCT05663723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group with the IV and V LED board
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
Study NCT06505265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study NCT05768555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 40 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
Study NCT05768555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 25 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
Study NCT05768555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 0 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
Study NCT06648096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
Study NCT06649552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Psychiatric and psychological diagnostic tests
Description: French validation of the SPI-CY
Study NCT05663723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group with the IV, V and Violet LED board
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
Study NCT05663723 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group with LED board without emitting light
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
Study NCT04941378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: One time infusion of OTL38
Study NCT04491253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support for diabetes self-management
Description: Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
Study NCT05564793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-implantation planning
Description: ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT
Study NCT05564793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-implantation assessment
Description: ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
Study NCT05564793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post-implantation assessment
Description: ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
Study NCT04956770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation surgery
Description: The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic
Study NCT04671173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of the Intra-Compartmental Pressure with the MY01 device
Description: All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device.
Study NCT05914324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phefumla device
Description: The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.
Study NCT05914324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LB-01 device
Description: The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
Study NCT06264310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo SC injection
Study NCT06264310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Study NCT05638035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonografi, Sarcopenia measurement, Zebris
Description: The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2.
Study NCT06324305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy (PPV) and drainage of subretinal fluid
Description: Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
Study NCT05183555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET/CT
Description: 68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
Study NCT05837026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)
Description: The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts.
Study NCT05837026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as Usual (CAU)
Description: Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
Study NCT05033561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2
Description: Novel Oral Poliomyelitis Type 2 Vaccine
Study NCT05033561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nOPV2
Description: Novel Oral Poliomyelitis Type 2 Vaccine
Study NCT05455996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA-assisted therapy
Study NCT06391086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS® Neuronavigation-guided focused ultrasound system
Description: The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
Study NCT05683262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection
Description: Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
Study NCT05683262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided coccygeal nerve block
Description: Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.
Study NCT05683262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block
Description: After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
Study NCT05018273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
Study NCT06168604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Identification and Communication Toolkit
Description: The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist
Study NCT06168604 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Promotion Program
Description: The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
Study NCT06630689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Full Body Massage
Description: Applying massage after phototherapy
Study NCT06630689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Full Body Massage
Description: Oil Full Body Massage
Study NCT05968742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence of oral hygiene on select teeth
Description: Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 10mg once daily via oral ingestion
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 2.5mg twice daily via oral ingestion
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Injectable Solution
Description: 40mg once daily via subcutaneous injection
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin Injectable Solution
Description: 4500 IU once daily via subcutaneous injection
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin Injectable Solution
Description: 5000 IU once daily via subcutaneous injection
Study NCT06370273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Injectable Product
Description: 2.5 mg once daily via subcutaneous injection
Study NCT06288477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A cotton pellet moistened with full-strength FC
Description: A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
Study NCT05504083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
Study NCT06288477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Putty
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
Study NCT05504083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzbromarone
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Study NCT04941378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoperative imaging camera system
Description: intraoperative imaging camera system
Study NCT05153733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIFRAM implant
Description: Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
Study NCT06245044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help
Study NCT06245044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #1
Description: Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.